Free tool
Cell therapy stocks
We cover 7 companies grouped under the Cell therapy theme. The median market value in the group is $98.77M. Across the group, the median move over the past trading day is +2.35%. Price change over the past year runs from −57.0% to +99.1% across the middle 80 percent of the group, with a median of −19.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% | Nov 11, 2026 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% | Nov 5, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% | Aug 27, 2026 |
| ATRA | Atara Biotherapeutics, Inc. | $98.77M | Micro cap | −19.61% | Nov 12, 2026 |
| INKT | MiNK Therapeutics, Inc. | $60.32M | Micro cap | −21.89% | Nov 12, 2026 |
| TVGN | Tevogen Inc. | $44.34M | Micro cap | −84.85% | Nov 13, 2026 |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −12.71% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.